FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586153616> ?p ?o ?g. }

• W2586153616 abstract "Abstract Abstract 308 Loss-of-function somatic mutations in Addition of Sex Combs Like 1 (ASXL1) occur in a subset of patients with myeloid malignancies, most commonly in myelodysplastic syndrome (MDS). In addition, germline mutations in ASXL1 are observed in patients with Bohring-Opitz Syndrome, a developmental disorder characterized by neurologic and skeletal abnormalities. Previous work characterizing a constitutive gene-trap Asxl1 model was notable for significant perinatal lethality of Asxl1−/− mice with evidence of an overt hematopoietic phenotype in surviving mice. Given the lack of detailed data on the hematopoietic phenotype of Asxl1 loss in vivo, we created a murine model for conditional knockout of Asxl1 for tissue- and temporal-specific deletion with 4 different Cre recombinase alleles. We crossed our conditional Asxl1 allele to EIIa-cre to generate mice with germline loss of Asxl1; this revealed embryonic lethality of mice with homozygous germline Asxl1 loss. Mice with heterozygous germline deletion of Asxl1 were viable and fertile although a significant proportion had cranio-facial abnormalities. Timed-sacrifice of pregnant mothers from heterozygous EIIa-cre Asxl1+/− crosses revealed that homozygous Asxl1−/− pups survived to 18–20.5 days post-coitus, with all embryos characterized by craniofacial abnormalities including anopthalmia, microcephaly, cleft palates, and mandibular malformations similar to those seen with Bohring-Opitz syndrome. We then generated mice with conditional Asxl1 deletion in the hematopoietic compartment by crossing floxed mice with Vav-cre recombinase mice for hematopoietic deletion at birth, and with Mx1-cre mice for inducible deletion of Asxl1. Deletion of Asxl1 in both systems resulted in complete loss of Asxl1 as assessed by Western blot. In both models we noted progressive development of leukopenia and anemia in mice with homozygous loss of Asxl1 compared to age-matched controls (Figure). This was associated with extramedullary hematopoiesis and morphologic evidence of myeloid, erythroid, and megakaryocytic dysplasia, similar to that observed in human MDS (Figure). Flow cytometry revealed a progressive increase in immunophenotypically-defined multipotent progenitors (Lineage-negative, Sca1+, cKIT+, CD150-, CD48+ cells) in bone marrow and spleen of knockout (KO) mice. Characterization of HSC's from 6-week old Vav-cre Asxl1−/− mice using serial competitive transplantation revealed a competitive disadvantage with transplantation of SLAM+ cells from 6-week old KO mice. A subset of Vav-cre Asxl1−/− mice developed a transplantable, monocytic-like leukemia beyond 6 months of age which was characterized by both proliferative and dysplastic features. Restriction of Asxl1 deletion to the megakaryocytic compartment using Pf4-cre revealed an age-specific decline in platelet production in Pf4-cre Asxl1−/− mice compared to age-matched controls, and a concomitant increase in bone marrow megakaryocytes in KO mice. Consistent with previous in vitro studies, hematopoietic-specific deletion of Asxl1 was associated with a marked decrease in H3K27me3 as assessed by histone Western blots of murine splenocytes and H3K27me3 ChIP-Seq of myeloid progenitors from 1 year-old Vav-cre Asxl1−/− mice compared with littermate controls. RNA-Seq from myeloid progenitors was integrated with H3K4me3/K27me3 ChIP-Seq to identify gene targets of Asxl1 loss associated with myelodysplasia. Given that MDS patients frequently present with concomitant ASXL1 and TET2 mutations, Vav-cre Asxl1fl/fl mice were also crossed with mice bearing floxed alleles of Tet2. Mice with combined hematopoietic-specific deletion of both Asxl1 and Tet2 developed bone marrow failure and hastened death compared with age-matched, single-gene deleted counterparts at 25 to 40 weeks of age. The findings here reveal that hematopoietic-specific deletion of Asxl1 results in progressive ineffective hematopoiesis, an increase in hematopoietic progenitors, a propensity for leukemic transformation with age, and morphologic features of human MDS (Figure). Combining Asxl1 deletion with loss of Tet2, a combined genotype present in at least 5% of patients with de novo MDS, resulted in shorter latency, progressive MDS. These data suggest that these two models represent novel, genetically accurate models of MDS amenable to epigenomic, functional and preclinical therapeutic studies. Disclosures: No relevant conflicts of interest to declare." @default.
• W2586153616 created "2017-02-17" @default.
• W2586153616 creator A5001079998 @default.
• W2586153616 creator A5009363039 @default.
• W2586153616 creator A5025595346 @default.
• W2586153616 creator A5025660159 @default.
• W2586153616 creator A5039241152 @default.
• W2586153616 creator A5045138685 @default.
• W2586153616 creator A5049360628 @default.
• W2586153616 creator A5052953228 @default.
• W2586153616 creator A5056665352 @default.
• W2586153616 creator A5058470461 @default.
• W2586153616 creator A5063866044 @default.
• W2586153616 creator A5068041831 @default.
• W2586153616 creator A5069334303 @default.
• W2586153616 creator A5073337663 @default.
• W2586153616 creator A5074786703 @default.
• W2586153616 creator A5084846489 @default.
• W2586153616 creator A5084923564 @default.
• W2586153616 creator A5085098439 @default.
• W2586153616 date "2012-11-16" @default.
• W2586153616 modified "2023-09-26" @default.
• W2586153616 title "Conditional Deletion of Asxl1 Results in Myelodysplasia" @default.
• W2586153616 doi "https://doi.org/10.1182/blood.v120.21.308.308" @default.
• W2586153616 hasPublicationYear "2012" @default.
• W2586153616 type Work @default.
• W2586153616 sameAs 2586153616 @default.
• W2586153616 citedByCount "0" @default.
• W2586153616 crossrefType "journal-article" @default.
• W2586153616 hasAuthorship W2586153616A5001079998 @default.
• W2586153616 hasAuthorship W2586153616A5009363039 @default.
• W2586153616 hasAuthorship W2586153616A5025595346 @default.
• W2586153616 hasAuthorship W2586153616A5025660159 @default.
• W2586153616 hasAuthorship W2586153616A5039241152 @default.
• W2586153616 hasAuthorship W2586153616A5045138685 @default.
• W2586153616 hasAuthorship W2586153616A5049360628 @default.
• W2586153616 hasAuthorship W2586153616A5052953228 @default.
• W2586153616 hasAuthorship W2586153616A5056665352 @default.
• W2586153616 hasAuthorship W2586153616A5058470461 @default.
• W2586153616 hasAuthorship W2586153616A5063866044 @default.
• W2586153616 hasAuthorship W2586153616A5068041831 @default.
• W2586153616 hasAuthorship W2586153616A5069334303 @default.
• W2586153616 hasAuthorship W2586153616A5073337663 @default.
• W2586153616 hasAuthorship W2586153616A5074786703 @default.
• W2586153616 hasAuthorship W2586153616A5084846489 @default.
• W2586153616 hasAuthorship W2586153616A5084923564 @default.
• W2586153616 hasAuthorship W2586153616A5085098439 @default.
• W2586153616 hasConcept C102230213 @default.
• W2586153616 hasConcept C104317684 @default.
• W2586153616 hasConcept C109159458 @default.
• W2586153616 hasConcept C109825262 @default.
• W2586153616 hasConcept C125929170 @default.
• W2586153616 hasConcept C127716648 @default.
• W2586153616 hasConcept C141035611 @default.
• W2586153616 hasConcept C164659718 @default.
• W2586153616 hasConcept C180754005 @default.
• W2586153616 hasConcept C182704531 @default.
• W2586153616 hasConcept C2779282312 @default.
• W2586153616 hasConcept C28328180 @default.
• W2586153616 hasConcept C502942594 @default.
• W2586153616 hasConcept C54355233 @default.
• W2586153616 hasConcept C86803240 @default.
• W2586153616 hasConceptScore W2586153616C102230213 @default.
• W2586153616 hasConceptScore W2586153616C104317684 @default.
• W2586153616 hasConceptScore W2586153616C109159458 @default.
• W2586153616 hasConceptScore W2586153616C109825262 @default.
• W2586153616 hasConceptScore W2586153616C125929170 @default.
• W2586153616 hasConceptScore W2586153616C127716648 @default.
• W2586153616 hasConceptScore W2586153616C141035611 @default.
• W2586153616 hasConceptScore W2586153616C164659718 @default.
• W2586153616 hasConceptScore W2586153616C180754005 @default.
• W2586153616 hasConceptScore W2586153616C182704531 @default.
• W2586153616 hasConceptScore W2586153616C2779282312 @default.
• W2586153616 hasConceptScore W2586153616C28328180 @default.
• W2586153616 hasConceptScore W2586153616C502942594 @default.
• W2586153616 hasConceptScore W2586153616C54355233 @default.
• W2586153616 hasConceptScore W2586153616C86803240 @default.
• W2586153616 hasLocation W25861536161 @default.
• W2586153616 hasOpenAccess W2586153616 @default.
• W2586153616 hasPrimaryLocation W25861536161 @default.
• W2586153616 hasRelatedWork W2036038124 @default.
• W2586153616 hasRelatedWork W2086942378 @default.
• W2586153616 hasRelatedWork W2236323615 @default.
• W2586153616 hasRelatedWork W2517303473 @default.
• W2586153616 hasRelatedWork W2519202495 @default.
• W2586153616 hasRelatedWork W2526523682 @default.
• W2586153616 hasRelatedWork W2533774740 @default.
• W2586153616 hasRelatedWork W2534851901 @default.
• W2586153616 hasRelatedWork W2549907925 @default.
• W2586153616 hasRelatedWork W2555379581 @default.
• W2586153616 hasRelatedWork W2579125809 @default.
• W2586153616 hasRelatedWork W2582318613 @default.
• W2586153616 hasRelatedWork W2748224455 @default.
• W2586153616 hasRelatedWork W2893252425 @default.
• W2586153616 hasRelatedWork W2991773900 @default.
• W2586153616 hasRelatedWork W3010119760 @default.
• W2586153616 hasRelatedWork W3099998724 @default.
• W2586153616 hasRelatedWork W3182862451 @default.
• W2586153616 hasRelatedWork W3200588953 @default.
• W2586153616 isParatext "false" @default.

• next